Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,295 papers from all fields of science
Search
Sign In
Create Free Account
Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
Known as:
PROSTVAC-F
, rFowlpox-PSA(L155)/TRICOM Vaccine
A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Cytotoxic T-Lymphocytes
Gene Expression Regulation
Prostate-Specific Antigen
T-Cell Activation
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Immunotherapy and Targeted Therapies in Advanced Castration Resistant Prostate Cancer
J. Bellmunt
,
I. Moreno
2017
Corpus ID: 78409923
Prostate Cancer (PC) is the second most frequent type of cancer in men worldwide. The therapeutic strategy for advanced PC…
Expand
2015
2015
Prostate-specific antigen pox virus vaccination for recurrent prostate cancer.
M. Wirth
,
M. Froehner
European Urology
2015
Corpus ID: 27389890
2014
2014
Prostate Cancer Vaccines Generated with the Disruptive RNActive® Technology Follow the Path Paved by Sipuleucel-T and Prostvac-VF
K. Kallen
2014
Corpus ID: 68015482
Somewhat surprisingly, the first active cancer immunotherapy was approved with sipuleucel-T, an autologous cell therapy, in…
Expand
2013
2013
[Immunotherapy: a therapeutic revolution against prostate cancer?].
M. Pracht
,
F. Herrera
,
T. Tawadros
,
D. Berthold
Revue medicale suisse
2013
Corpus ID: 38892781
The interaction between the immune system and cancer was an area of research interest for several decades. The recent U.S. Food…
Expand
2013
2013
Abstract A21: Active immunotherapy with PROSTVAC® demonstrates potent antitumor efficacy in a mouse model of prostate cancer.
R. Rountree
,
S. Mandl
,
+8 authors
A. Delcayre
2013
Corpus ID: 72459349
BN ImmunoTherapeutics (BNIT) specializes in developing novel active immunotherapies for cancer. These therapies use recombinant…
Expand
Review
2012
Review
2012
Current status of immunological approaches for the treatment of prostate cancer
C. Drake
,
E. Antonarakis
Current Opinion in Urology
2012
Corpus ID: 205841372
Purpose of review The recent Food and Drug Administration approval of sipuleucel-T for metastatic castration-resistant prostate…
Expand
Review
2011
Review
2011
Recent advances in immunotherapy for the treatment of prostate cancer
G. Sonpavde
,
N. Agarwal
,
T. Choueiri
,
P. Kantoff
Expert Opinion on Biological Therapy
2011
Corpus ID: 207482230
Introduction: Prostate cancer vaccines attempt to induce cancer-specific systemic immune responses and represent a new class of…
Expand
Review
2006
Review
2006
Management of high risk metastatic prostate cancer: the case for novel therapies.
T. Brand
,
A. Tolcher
Journal of Urology
2006
Corpus ID: 24524888
2005
2005
A phase II study of PROSTVAC-VF vaccine, and the role o f GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC)
J. Gulley
,
N. Todd
,
W. Dahut
,
J. Schlom
,
P. Arlen
2005
Corpus ID: 78776412
2504 Background: Vaccine strategies represent a novel therapeutic approach for the treatment of metastatic AIPC. Preclinical and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE